Replies to post #358386 on Amarin Corp Plc (AMRN)

[fsulevine]

Wow. Actually had a better week than the generics. Thank you for the update Raf! Now if we can just get some positive news on Prepare-It 2, China, court decisions, etc…

[Number sleven]

Raf, Thanks for the numbers. Interesting, Hikma has been flat for weeks. DRL is increasing share size.
Anyone have an opinion or actual information as to why?
Sleven,

[ralphey]

These RX numbers themselves reveal infringement - there is no way that 25% of RX's are for VHTG

[rafunrafun]

Scripts for week ending October 29, 2021

Overall drug TRx -1.0% w/w

Vascepa
TRx 77,615; -4.0% (-3,260) w/w; -17.0% y/y
NRx 34,840; -4.5% (-1,623) w/w; -19.2% y/y
Ref 42,775; -3.7% (-1,637) w/w; -15.1% y/y

Lovaza (Generic & Brand)
TRx 62,471; -0.5% (-308) w/w; -1.1% y/y
NRx 30,450; -1.0% (-298) w/w; -7.3% y/y
Ref 32,021; -0.0% (-10) w/w; +5.7% y/y

Generic Vascepa
TRx 21,149; +2.5% (+517) w/w; As % of total V: 21.4%
NRx 12,116; +2.4% (+287) w/w; As % of total V: 25.8%
Ref 9,034; +2.6% (+230) w/w; As % of total V: 17.4%

Generic Vascepa by Manufacturer
Hikma - TRx 12,555 (-247); Generic share 59.4%; Total V share 12.7%
Reddy - TRx 8,594 (+764); Generic share 40.6%; Total V share 8.7%

TRx Vascepa + Generic Vascepa
TRx 98,764; -2.7% (-2,743)
NRx 46,956; -2.8% (-1,337)
Ref 51,808; -2.6% (-1,407)